Skip to main content
Top
Published in: BMC Health Services Research 1/2018

Open Access 01-12-2018 | Research article

A simulation tool for better management of retinal services

Authors: Eren Demir, David Southern, Aimee Verner, Winfried Amoaku

Published in: BMC Health Services Research | Issue 1/2018

Login to get access

Abstract

Background

Advances in the management of retinal diseases have been fast-paced as new treatments become available, resulting in increasing numbers of patients receiving treatment in hospital retinal services. These patients require frequent and long-term follow-up and repeated treatments, resulting in increased pressure on clinical workloads. Due to limited clinic capacity, many National Health Service (NHS) clinics are failing to maintain recommended follow-up intervals for patients receiving care. As such, clear and robust, long term retinal service models are required to assess and respond to the needs of local populations, both currently and in the future.

Methods

A discrete event simulation (DES) tool was developed to facilitate the improvement of retinal services by identifying efficiencies and cost savings within the pathway of care. For a mid-size hospital in England serving a population of over 500,000, we used 36 months of patient level data in conjunction with statistical forecasting and simulation to predict the impact of making changes within the service.

Results

A simulation of increased demand and a potential solution of the ‘Treat and Extend’ (T&E) regimen which is reported to result in better outcomes, in combination with virtual clinics which improve quality, effectiveness and productivity and thus increase capacity is presented. Without the virtual clinic, where T&E is implemented along with the current service, we notice a sharp increase in the number of follow-ups, number of Anti-VEGF injections, and utilisation of resources. In the case of combining T&E with virtual clinics, there is a negligible (almost 0%) impact on utilisation of resources.

Conclusions

Expansion of services to accommodate increasing number of patients seen and treated in retinal services is feasible with service re-organisation. It is inevitable that some form of initial investment is required to implement service expansion through T&E and virtual clinics. However, modelling with DES indicates that such investment is outweighed by cost reductions in the long term as more patients receive optimal treatment and retain vision with better outcomes. The model also shows that the service will experience an average of 10% increase in surplus capacity.
Appendix
Available only for authorised users
Literature
2.
go back to reference Owen CG, Jarrar Z, Wormald R, Cook DG. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96:752–6.CrossRef Owen CG, Jarrar Z, Wormald R, Cook DG. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96:752–6.CrossRef
3.
go back to reference Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.CrossRef Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.CrossRef
4.
go back to reference Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663–71.CrossRef Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663–71.CrossRef
5.
go back to reference Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology. 2013;120:S3–7.CrossRef Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology. 2013;120:S3–7.CrossRef
6.
go back to reference Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134–40.CrossRef Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134–40.CrossRef
7.
go back to reference Rush RB, Simunovic MP, Vandiver L, Aragon AV 2nd, Ysasaga JE. Treat-and-extend bevacizumab for neovascular age related macular degeneration: the importance of baseline characteristics. Retina. 2014;34:846–52.CrossRef Rush RB, Simunovic MP, Vandiver L, Aragon AV 2nd, Ysasaga JE. Treat-and-extend bevacizumab for neovascular age related macular degeneration: the importance of baseline characteristics. Retina. 2014;34:846–52.CrossRef
8.
go back to reference Hatz K, Prünte C. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100:1341–5.CrossRef Hatz K, Prünte C. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100:1341–5.CrossRef
12.
go back to reference Amoaku W, Blakeney S, Freeman M, Gale R, Johnston R, Kelly SP, McLaughlan B, Sahu D, Varma D. Action on AMD: Optimising patient management: act now to ensure current and continual delivery of best possible patient care. Eye. 2012;26:S1–S21.CrossRef Amoaku W, Blakeney S, Freeman M, Gale R, Johnston R, Kelly SP, McLaughlan B, Sahu D, Varma D. Action on AMD: Optimising patient management: act now to ensure current and continual delivery of best possible patient care. Eye. 2012;26:S1–S21.CrossRef
14.
go back to reference Trikha S, Macgregor C, Jeffery M, Kirwan J. The Portsmouth based glaucoma refinement scheme: a role for virtual clinics in the future? Eye. 2012;26:1288–94.CrossRef Trikha S, Macgregor C, Jeffery M, Kirwan J. The Portsmouth based glaucoma refinement scheme: a role for virtual clinics in the future? Eye. 2012;26:1288–94.CrossRef
16.
go back to reference Kotecha A, Baldwin A, Brookes J, Foster PJ. Experiences with developing and implementing a virtual clinic for glaucoma care in an NHS setting. Clin Ophthalmol. 2015;9:1915–23.CrossRef Kotecha A, Baldwin A, Brookes J, Foster PJ. Experiences with developing and implementing a virtual clinic for glaucoma care in an NHS setting. Clin Ophthalmol. 2015;9:1915–23.CrossRef
17.
go back to reference Wright HR, Diamond JP. Service innovation in glaucoma management: using a web-based electronic patient record to facilitate virtual specialist supervision of a shared care glaucoma programme. Br J Ophthalmol. 2015;99:313–7.CrossRef Wright HR, Diamond JP. Service innovation in glaucoma management: using a web-based electronic patient record to facilitate virtual specialist supervision of a shared care glaucoma programme. Br J Ophthalmol. 2015;99:313–7.CrossRef
18.
go back to reference Tsaousis KT, Empeslidis T, Konidaris VE, Kapoor B, Deane J. The concept of virtual clinics in monitoring patients with age-related macular degeneration. Acta Ophthalmol. 2016;94:353–5.CrossRef Tsaousis KT, Empeslidis T, Konidaris VE, Kapoor B, Deane J. The concept of virtual clinics in monitoring patients with age-related macular degeneration. Acta Ophthalmol. 2016;94:353–5.CrossRef
21.
go back to reference Salvage S. The flaw of averages: why we underestimate risk in the face of uncertainty. New Jersey: Wiley; 2009. Salvage S. The flaw of averages: why we underestimate risk in the face of uncertainty. New Jersey: Wiley; 2009.
Metadata
Title
A simulation tool for better management of retinal services
Authors
Eren Demir
David Southern
Aimee Verner
Winfried Amoaku
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2018
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-018-3560-5

Other articles of this Issue 1/2018

BMC Health Services Research 1/2018 Go to the issue